1 drug(s) with this reaction
1,745 total reports
Acute Myeloid Leukaemia has been reported as an adverse reaction across 1 drug(s) manufactured by Abbvie Inc in the FDA Adverse Event Reporting System (FAERS) database. A combined total of 1,745 adverse event reports mention acute myeloid leukaemia in connection with Abbvie Inc products.
This page provides a breakdown of which Abbvie Inc drugs are most commonly associated with acute myeloid leukaemia, along with report counts and links to detailed safety analyses for each medication. Understanding which drugs from a single manufacturer share a common adverse reaction can help patients and healthcare providers identify potential class-wide safety patterns.
The following Abbvie Inc drugs have acute myeloid leukaemia listed in their FDA adverse event reports, sorted by report count:
In addition to acute myeloid leukaemia, the following adverse reactions have been reported across Abbvie Inc's drug portfolio:
1 drug(s) manufactured by Abbvie Inc have acute myeloid leukaemia listed in their FDA adverse event reports: VENETOCLAX.
There are a combined 1,745 reports of acute myeloid leukaemia across 1 Abbvie Inc drug(s) in the FDA adverse event database.